Antengene和Junshi将ATG-037和JS-207合并进行中国试验,以治疗耐免疫疗法的固态肿瘤。 Antengene and Junshi launch China trial combining ATG-037 and JS207 to treat solid tumors resistant to immunotherapy.

Antengene和Junshi生物科学公司在中国大陆启动了临床合作,以测试Antengene口服CD73抑制剂ATG-037和Junshi的PD-1/VEGF双性抗体JS207在固态肿瘤患者中的结合情况。 Antengene and Junshi Biosciences have launched a clinical collaboration in mainland China to test the combination of Antengene’s oral CD73 inhibitor ATG-037 and Junshi’s PD-1/VEGF bispecific antibody JS207 in solid tumor patients. 该研究旨在评估药物的协同效应,针对免疫检查点、抗血管诱发和腺素代导免疫抑制。 The study aims to evaluate the drugs’ synergistic effects by targeting immune checkpoints, anti-angiogenesis, and adenosine-mediated immunosuppression. 早期数据显示,ATG-037具有有利的安全特征和组织高渗透度,在抗CPI的黑素瘤和NSCLC分别实现了33.3%和21.4%的客观反应率,并做出了持久反应。 Early data show ATG-037, which has a favorable safety profile and superior tissue penetration, achieved objective response rates of 33.3% and 21.4% in CPI-resistant melanoma and NSCLC, respectively, with durable responses. 联署材料207显示,在一线PD-L1呈阳性的NSCCL中,目标回复率为58.1%。 JS207 demonstrated a 58.1% objective response rate in first-line PD-L1-positive NSCLC. 该伙伴关系力求改善先前免疫治疗失败的患者的治疗结果。 The partnership seeks to improve outcomes for patients who have failed prior immunotherapies.